Although single agent dasatinib has minimal activity in ovarian cancer clinical trial [58], a current trial assessing clinical activity of dasatinib includes OCCC patients and their ARID1A expression status (NCT02059265). This evidence concerns the gene ARID1A and ovarian cancer.